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ABSTRACT
Objective: The aim of this study is to prepare oral controlled release (CR) of mucoadhesive alginate microbeads encapsulating fluvastatin by 
gastroretention technology.
Methods: The mucoadhesive microbeads containing fluvastatin were produced using emulsification internal gelation technique. The effect of 
different variables such as sodium alginate concentration and its combination with other hydrophilic polymers, and the effect of various curing agents 
on particle size, entrapment efficiency, and in vitro studies were evaluated.
Results: There was no marked change in drug entrapment efficiency, and dissolution studies occur during the stability studies of fluvastatin. The 
in vitro results give data that improvement in the CR of the drug from microbeads compared with marketed tablet. Hence, in this regard, to minimize 
the frequency of drug administration to reduce side effects. The optimum condition for the preparation of stable alginate beads and produce CR 
manner was occurred at a higher concentration of combined polymer mixture in equal ratios, i.e., 3% w/v. Infrared spectroscopic study (Fourier 
transform infrared) confirmed the no incompatibility between drug and other excipients. X-ray diffraction study and differential scanning calorimetry 
were provided evidence that successful entrapment of drug into the alginates microbeads and drug converted into amorphous nature. The efficiency 
of mucoadhesion strength of microbeads was determined by wash-off study.
Conclusion: The kinetic modeling of the release data indicates drug release from the microbeads follow anomalous transport mechanism and super 
Case-II transport mechanism. Drug release is a function of pH dependent and controlled drug release depends on type and concentration of polymer 
blend and curing agents. The release kinetics of drug from the alginate beads followed zero order.
Keywords: Fluvastatin, Emulsification internal gelation, Sodium alginate, Hydroxypropyl methylcellulose K4M, In vitro wash off study and swelling 
index.
INTRODUCTION
Orally administrated solid dosage forms possess large individual 
differences in the rate of bioavailability of many drugs, this occurs 
mostly because of the large variable gastrointestinal (GI) transit time 
of a tablet/capsule. In contrast to this, mucoadhesive drug delivery 
system designed to reduce both intra- and inter-subject variability in 
absorption of drug, to prevent sudden release of drug and provides 
drug release in controlled manner.
The polymers and transporters utilized in the arrangement are nontoxic, 
promptly accessible, and usually noncostly. Among completely various 
different polymers, Na-alginate remains as a polymer of decision for 
bead production. It is a bioerodible polyacid that has gained a unique 
property of gel network inside the sight of multivalent cations, for 
example, aluminum ions (trivalent) and calcium ions (divalent) in fluid 
media that happen chiefly at intersections in the G-G sequence rich 
chain region named as the “egg box junction.” Bead production is gotten 
by the inclusion of the medication into a gel dispersion system, and the 
hydrophilic colloids at that point connect with polyvalent metal ions to 
obtain insoluble colloidal complexes (calcium alginate), drops that may 
cause to accelerate in the formation of cross-linked beads.
For soluble drug, carbopol gel could extend the release time but release 
pattern has significant fluctuation. Hence, in this study, polymer blend 
used containing hydroxypropyl methylcellulose (HPMC) K4M and 
sodium alginate was used in equal ratios and which acts as a matrix 
former to improve the rate of release of fluvastatin sodium from 
matrices. For many medications that are ingested basically from the 
proximal small intestine, controlled discharge in stomach would bring 
about improved [1-3] the rate of bioavailability. Different methodologies 
available to increase the gastrointestinal residence time, few of which 
include floatation system or swellable system, gas rafting system, and 
mucoadhesive system.
Fluvastatin sodium is an antilipidemic agent that competitively inhibits 
hepatic enzyme 3-hydroxy-3-methylglutaryl-coenzyme a reductase. It 
belongs to a class of medications called statins and is used to reduce plasma 
cholesterol levels and prevents cardiovascular diseases [4]. Its short 
biological half-life (3 h) and but it possesses low therapeutic concentration 
at the target site due to low rate of bioavailability (24%–29%) because of 
extensive presystemic metabolism, less GI residence time. The nature of 
drug is lipophilic. Nonetheless; this compound has a variable elimination 
half-life time around 1–6 h in people, requiring a dosing recurrence 20–40 
mg twice a day. In the perspective on these attributes, numerous endeavors 
have been made to develop sustained-release (SR)/CR preparation with 
broadened clinical impacts and diminish dosing recurrence [5] and also 
prolong the duration of action of drug.
The emulsification internal gelation commonly formed by cross-linking 
of sodium alginate, yet the subsequent aluminum alginate microbead 
is absolutely compact, creating it very difficult to control the release of 
medication for a long period of time compared to other curing agents. 
These issues are generally confined by blending sodium alginate 
with completely other polymers, for instance, HPMC K4M, sodium 
carboxymethyl cellulose, and Carbopol 934P.
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Sodium alginate polymer is a linear polysaccharide and unbranched, 
biocompatible, versatile, and non-toxic matrix of gel that protects the 
active components of factors such as humidity and heat and thereby 
improving stability and bioavailability [6]. Because of non-regular 
block carboxyl groups with the sodium alginate chains, these chains 
are highly prone to cross-link with divalence/trivalence cations which 
enables to form reticular hydrogel structure; hence, sodium alginate 
is broadly used mainly in application of the controlled drug delivery 
system nowadays. HPMC is a non-ionic cellulose-based compound 
because of its surface activity and high swelling capacity it makes to 
enhance drug loading and prolongs drug release.
It was discovered that the biocompatible microspheres had additional 
high selectivity for discharge of drug substance, in which they restrict 
drug release at the simulated gastric fluid (pH=1.2), however, permitted 
full maximum rate of the drug at the premises of higher pH atmosphere, 
i.e., intestines, implying that the materials are harmless and safe as a 
drug carrier for controlled release (CR) pattern of drug. This kind of 
science is reasonable for financially savvy make, prompting a desire that 
the methodology might be useful for scale-up to industrial production.
MATERIALS AND METHODS
Materials
The pure drug fluvastatin was obtained from AurobindoPharma 
Limited, Hyderabad, Telangana state, India. HPMC, sodium alginate 
was purchased from HiMedia, Mumbai, Carbopol 934, barium chloride 
(BaCl2.2H2O), calcium chloride (CaCl2.2H2O), aluminum chloride 
(AlCl3.6H2O), ethanol, and chloroform solution were obtained from 
QualigensFine Chemicals, Mumbai. All chemical agents used belonging 
to analytical high-grade quality.
Equipments
Digital electronic weighing balance (0.1 mg sensitive), Sonicator (Remi 
model, Mumbai, India), Sigma Blade Homogenizer (Remi model, India), 
Dessiccator (Borosilicate, Mumbai), Tablet disintegrating test apparatus 
(USP model, India), Dissolution test apparatus USP (model TDT-08L, 
Electro-lab, Mumbai, India), and Sonicator, Remi model, India. Double beam 
ultraviolet (UV)-visible spectrophotometer, Shimadzu, scanning electron 
microscope (SEM; S4100, Hitachi, Japan), X-ray diffractometer, Bruker 
spectrophotometer (Model-220, Germany) and Syringe needle 23 G, etc.
Preparation of fluvastatin microbeads
The fluvastatin based alginate microbeads were prepared by choosing 
emulsification internal gelation method. The mucoadhesive microbeads 
were prepared by taking fluvastatin 40 mg dissolved in purified mineral 
water and this solution was added to white viscous solution which is 
already prepared and this contained sodium alginate polymer solution. 
This polymer solution is prepared by taking sodium alginate polymer 
and dissolved in water by subjecting to homogenization process until 
sodium alginate is completely dissolves then keeps this homogenous 
polymer viscous solution inside sonicator to remove air bubbles 
completely. To the above physical mixture solution which is placed in 
a beaker, add selected cross-linking agent at 5% w/v concentration 
slowly into above glass beaker which is stirred with high frequency 
Remi modeled sigma blade homogenizer and keep on rotation for long 
time until it forms smooth, fine viscous solution completely and again 
keep the above solution for sonication up to 1–2 h to get free bubble 
solution finally. The above physical mixture solution containing drug 
with selected polymer of known concentration and cross-linking agent 
take into 10 ml syringe which is fixed with needle 22 gauze and pressed/
extruded dropwise into 250 ml glass beaker which containing mixture 
of 100 ml light liquid paraffin oil (acts as a emulsifying agent) with 
1.5% w/v concentration of span 80 and glacial acetic acid at 0.2% w/v. 
During the addition of drug-based polymer viscous solution dropwise, 
and it was sure to keep the minimum 10 cm distances between glass 
beaker and tip of needle throughout the process. The process of 
homogenization under 600 rpm by rotating with blade homogenizer 
was maintained continuously. After specified time, the above solution 
was filtered through filter paper placed over funnel, on filtration, it 
will form residue of insoluble high viscous smooth solid product and it 
was washed carefully 3–4 times with n-Hexane or chloroform solution 
to remove sticky fatty material on surface of small microbeads and 
these formed microbeads placed inside dessiccator until microbeads 
becomes completely dried.
In this current article, other hydrophilic polymers were also 
incorporated along with sodium alginate in equal ratios than alone 
sodium alginate polymer and different curing agents were added at 5% 
w/v concentration on optimized batch to evaluate the change in drug 
release pattern and other parameters, which were clearly mentioned 
in following Table 1.
CHARACTERIZATION STUDIES
Size distribution and size analysis
For determination of size distribution analysis, 200 mg of the cross-
linked fluvastatin alginate microbeads of various sizes in a formulation 
were subjected to sieving method using a range of standard sieves 
grades and arranged one by one according to their mesh size and start 
Table 1: Formulation composition and physicochemical properties of prepared fluvastatin microbeads










Sodium alginate FSF1 1:01 91.68 132.55±0.07 44.96±0.02 89.92±0.09
FSF2 1:1.5 93.89 146.36±0.05 37.94±0.04 94.85±0.06
FSF3 1:02 95.13 154.44±0.03 31.82±0.05 96.42±0.04
FSF4 1:03 96.47 168.47±0.06 24.46±0.03 97.84±0.07
Sodium alginate+HPMC K4M FSF5 1:01 92.12 135.13±0.05 44.13±0.09 88.26±0.05
FSF6 1:1.5 92.35 157.24±0.09 37.34±0.08 93.95±0.09
FSF7 1:02 94.27 168.49±0.08 32.23±0.09 97.66±0.08
FSF8 1:03 96.45 180.29±0.07 23.41±0.05 93.64±0.04
Sodium alginate+carbopol 934P FSF9 1:01 92.18 139.44±0.06 46.56±0.05 93.12±0.06
FSF10 1:1.5 94.56 156.47±0.09 37.66±0.09 92.90±0.05
FSF11 1:02 96.88 168.39±0.05 31.25±0.06 94.39±0.04
FSF12 1:03 98.32 179.33±0.06 23.47±0.04 93.38±0.06
Sodium alginate+NaCMC 
1100–1900Cps
FSF13 1:01 92.47 140.53±0.02 44.38±0.07 89.76±0.02
FSF14 1:1.5 96.28 156.33±0.04 37.66±0.04 94.15±0.03
FSF15 1:02 96.79 164.46±0.07 31.46±0.08 95.33±0.05
FSF16 1:03 97.16 178.46±0.02 24.13±0.04 96.52±0.03
Sodium alginate+HPMC K4M FSF17 1:03 96.36 174.32±0.05 23.27±0.04 93.08±0.07
Sodium alginate+HPMC K4M FSF18 1:03 96.23 167.25±0.05 23.43±0.03 93.72±0.06
*Batches FSF1 to FSF16 cured with 5% AlCl3+ with different polymersonly and FSF17 and FSF18 batches containing sodium alginate with HPMC K4M. and that 
cured with 5% w/v of BaCl2+ and 5% CaCl2+w/v. *All readings were taken in triplicate manner, i.e., n=3. Mean±SD. NaCMC: Sodium carboxymethyl cellulose, 
HPMC: Hydroxypropyl methylcellulose
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the machine continuously according to the standard procedure. The 
amount of uniformed microbeads which were retained on different 
individual sieves was taken out and weighed accurately. Finally, the 
mean particle size of the fluvastain microbeads was determined by 
given the following equation.
Mean particle size







Percent yield defined as the percent ratio of practical yield to the theoretical 





Estimation of drug content of microbeads
Accurately 100 mg of microbeads were exactly weighed and shifted to a 
cleaned dry mortar and powdered by continuous grinding and dissolved 
in 100 ml of freshly prepared pH 6.8 phosphate buffer solution and 
filtered, suitably diluted the absorbance of the above solution, absorbance 
was measured at 304 nm by UV-visible spectrophotometer for fluvastatin.
Entrapment efficiency of microbeads
Entrapment efficiency was resolved using the formula. For calculation 
of drug content, 40 mg of beads were placed in 100 ml of 6.8 phosphate 
buffer for complete swelling at 37°C. The fluvastatin based alginate 
beads were crushed in a glass mortar with pestle and the above solution 
was then kept for 2 h to extract the drug completely and centrifuged to 
separate polymeric debris using centrifuge apparatus for 30 min. The 
solution was filtered, the clear supernatant solution was measured 
fluvastatin content using a UV-visible spectrophotometer at 304 nm.
Entrapment efficeincy
Estimated percentage drug content
The

oritical percentage drug content
1 00
Drug loading





Estimated percent drug content was determined from the analysis 
of 100 mg microbeads, and the theoretical percent drug content 
was calculated from the utilized core:coat ratio in the formulation of 
microbeads.
Morphological characterization of microbeads (SEM studies)
Tests were sputter-covered with gold under a vacuum before perception 
with a SEM at an increasing speed voltage of 10 kV.
Fourier transform infrared (FTIR) spectra analysis studies
Infrared spectra were recorded by utilizing a TENSOR 27 FTIR 
spectrometer (Bruker, Horiba, Oberursel, Germany). Scans were recorded 
more than 400–4000 cm−1 wavenumbers with a resolution of 2 cm−1.
X-ray diffraction (XRD) studies
Pure fluvastatin sodium, microbeads loaded drugs were analyzed using 
an X-ray diffractometer (D8, Bruker, Germany) in the 2θ range 5–60° 
with a scanning velocity of 2° min−1.
Differential scanning calorimetry (DSC) studies
For the determination of DSC studies, the microbeads of known 
quantity (2 mg) were heated from 40°C to 275°C using a temperature 
rate of 10°C/min. A nitrogen purge of 100 ml/min was fixed.
Determination of swelling index
It was determined by measuring the difference between the initial 
diameter of the microbeads and final diameter of the beads at time t. It 











Sw = percentage of swelling of microbeads, Wt = weight of the microbeads 
at time t, and WO = initial weight of the microbeads.
In-vitro wash-off test for microbeads
The mucoadhesive strength property of the cross-linked alginate 
microbeads was determined by conducting in vitro wash-off test. For 
doing of this test, few modifications were done to the disintegration 
test apparatus test. This test should be mimic same body atmospheric 
physiology conditions and for this reason, two freshly prepared buffer 
medium were used. During procedure acidic solution of 0.1 N HCl was 
used for 8 h and this acid solution replaced fast with 6.8 phosphate 
buffer solution and same continued for another 8 h. The important 
step involved in this test is use of fresh goat mucous membrane which 
surround the intestine of 3 cm×3 cm was rounded paddle completely at 
down place and keep and spread 100 fluvastatin microbeads exactly over 
mucous specimen and this paddle was connected to horizontal iron rod, 
which is clung to shaft of disintegration test apparatus (USP model) in the 
right position. During continuous up and down movement of shaft which 
is connected to the paddle that holds microbeads on mucous membrane 
and glass beakers contain acidic medium of 900 ml capacity for the 
first 8 h and the apparatus run under the temperature of 37±0.5°C and 
movement of paddle up and down were maintained 60 rpm without fail. 
The microbeads which are having maximum adhesive strength will stick 
long time to mucous membrane and not having mucoadhesive strength 
means, the beads will get detached in between study planned for 8 h. The 
results of in vitro wash-off test of three batches are shown in Table 2.
Dissolution studies
To simulate the release of drug in both the human stomach and 
intestine atmosphere, in vitro studies were carried out under both 
acidic medium (pH 1.2) for the first 2 h and alkaline (pH 6.8 phosphate 
buffer) conditions as well as separately for next 10 h using dissolution 
test apparatus USP model. Dried fluvastatin microbeads were precisely 
weighed equivalent to 40 mg and transferred into the dissolution basket 
Table 2: In vitro wash-off test values for the fluvastatin sodium alginate microbeads prepared with combination of sodium alginate and 
HPMC K4M in 1:3 ratios by employing various cross-linking agents
Formulation Percent of alginate beads adhering to tissue at 5 times (h)
0.1 N HCl, pH 1.2 Phosphate buffer, pH 6.8
1 2 4 6 8 1 2 4 6 8
FSF8 68 (1.5) 57 (1.8) 47 (1.2) 38 (1.8) 26 (2.0) 94 (0.5) 87 (1.0) 79 (1.0) 66 (1.0) 57 (1.0)
FSF17 66 (1.0) 54 (1.8) 40 (1.1) 32 (1.5) 22 (1.0) 92 (0.5) 85 (1.0) 76 (1.2) 64 (1.8) 53 (1.2)
FSF18 62 (1.8) 50 (1.2) 38 (1.8) 24 (2.0) 16 (1.8) 91 (0.5) 80 (1.0) 71 (1.5) 59 (1.5) 47 (2.0)
Microbeads 
prepared with EVA
48 (1.2) 22 (1.4) 4 (1.0) - - 42 (0.5) 18 (1.6) 2 (0.2) - -
*Each reading was taken in triplicate, i.e., n=3, Mean±SD. EVA: Ethyl vinyl acetate, HPMC: Hydroxypropyl methylcellulose
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which composed of 900 ml freshly prepared dissolution mediums and 
paddle was rotated at 100 rpm under a temperature of 37±0.5°C. The 
dissolution medium containing drug released was sampled at various 
intervals of time up to 12 h by withdrawing sample hourly wise and then 
removed medium taking for sampling purposes and it was replaced by 
a fresh buffered medium with a similar quantity. The collected fluid 
was subjected to filtration by utilizing 0.22 µm filter paper, aliquots of 
filtrate were diluted suitably [7-9] and the absorbance reading of fluid 
was taken out using an UV-visible spectrophotometer by fixing the 
wavelength working at 304 nm. At last, the fluvastatin concentration 
was determined from the fluid using standardized calibration curve.
Kinetic studies
To evaluate the mechanism of drug discharge from the matrix tablets, 
the information got from the drug discharge studies was examined by 
the accompanying conditions. In all mathematical equations, Q is the 
measure of medication discharged at time t, Mt is the drug discharged 
at time t, M is the total measure of medication in the dosage form, F is 
the portion of the medication discharged at time t, K0 is the zero-order 
release rate constant, and “n” is the diffusion exponent type which 
demonstrating the mechanism of drug release. The value of n=0.45 
demonstrates Fickian type dispersion, the estimation of n somewhere 
in the range of 0.45–0.89 indicates anomalous transport and the value 
n=0.89 demonstrates Case-II transport model.
RESULTS AND DISCUSSION
On observation of micromeritic studies of alginate microbeads appeared 
as white, nearly spherical shape like and free-flowing of fluvastatin 
sodium microbeads were produced using the emulsification internal 
gelation method. The percentage yield varied from 91.68% to 98.32%, 
with the highest yield obtained for FSF12 batch. The results show that 
increase in concentration of polymer blend ratio improves product yield, 
i.e., concentration of polymer blend was forms direct proportional. However, 
mean particle size has been shown to be increased with increasing polymer 
blend concentration, which could be due to enhancement in relative 
viscosities of polymer. The flow property parameter values are mentioned 
in Table 1, the angles of repose were found in the range of 20.39±0.05–
28.26±0.06 (IP limits 25–30) showing that the blend of powder was freely 
flowing. The values for the Carr’s index were between 12.32±0.04% and 
15.87±0.06% (IP limits 11–15%) indicating that all fluvastatin batches of 
powder blends were having good compressibility values. The Hausner’s 
ratio was within the limits of 1.16±0.012–1.22±0.05 (IP limits 1.12–1.10). 
The results showed that all the batches showed good flow (rheological 
properties). The values of both tapped and bulk densities have shown good 
packing ability. The statistical data which is relavant to micromeritics of 
total formulations were shown in Table 3.
Effect of core:coat ratio on drug entrapment
In current article, a total of 18 batches have formulated and in all 
batches same quantity of drug was maintained and first four batches 
were designed only with combinations of drug and sodium alginate 
polymer (FSF1 to FSF4) was added. With different concentrations of 
sodium alginate ranging from 1%, 1.5%, 2%, to 3% w/v along with 
drug, DEE will be enhanced the reason for progressive increment in the 
first four batches due to the availability of abundant number of cross-
linking sites along polymer chains and it will drag more drug inside and 
maximum cross-linking taking place.
Entrapment efficiency
The percentage entrapment efficiency values for the first four batches 
ranged from 89.92±0.09% to 97.84±0.07%. Hence, based on above 
evidence, it was proved that with increase in the concentration of 
polymers, i.e., polymer blend an increase in the drug entrapment 
efficiency of the microbeads was observed. It also depends on type of 
crosslinker used. In current studies, the three different cross-linking 
agents naming AlCl3, BaCl2, and CaCl2 at 5% w/v level were used along 
with polymer blend as per described procedure. In above three curing 
agents, the different batches and AlCl3 which is used as curing agent 
from FSF1 to FSF16 batches only will show maximum entrapment 
efficiency 97.84±0.07% because of it will form tight compact 
microbeads and not allow any leakage of drug during process of 
homogenization, microbeads obtained with BaCl2 (FSF17 batch) show 
less DEE than FSF8 batch The entrapment efficiencies were generally 
higher for the formulations that cross-linked with Al3+ and Ca2+ as 
compared to the microbeads cross-linked with BaCl2 93.08±0.07% at 
the same concentrations of curing agents.
FTIR studies
The FTIR spectrum of pure fluvastatin sodium showed that characteristic 
peaks at wave numbers were 1013.16 cm−1, 3688.12 cm−1, 1214.96 cm−1, 
and 1481.32 cm−1 denoting stretching vibration of C-F stretching, 
O-H stretching, C-O stretching, and CH3 deformations, the peak at 
949.56 cm−1 occurs due to aryl-F functional group, 1013.76 cm−1 due 
to stretching vibration of C-F type, 949.56 cm−1 corresponds to aryl-F, 
1053.89 cm−1 due to C-F stretching type, 1154.47 cm−1 due to ether 
stretching, 1215 cm−1 represents amine (C-N) group, 1481.32 cm−1 due 
to CH3 deformation, 1579.87 cm−1 due to C=O stretching, 1620.28 cm−1 
due to the presence of carboxyl stretch C=O, 3375.41 cm−1 due to 
aryl-H, 3580.60 cm−1 due to C=O stretching, 3688.12 cm−1 due to O-H 
stretching type, and 3894.24 cm−1 due to O-H bending, respectively. 
The FTIR spectrum (Figs. 1-5) of optimized formulation showed that 
characteristic peaks at wave numbers were 1009.53 cm−1, 3028.37 cm−1 
indicates C-H fetching, 3644.11 cm−1, 1214.67 cm−1, and 1480.31 cm−1 
denoting stretching vibration of C-N stretching, O-H stretching, C-O 
Table 3: Flow properties of fluvastatin-based sodium alginate microbeads
Formulation Angle of repose (θ) Bulk density (g/cm3) Tapped density (g/cm3) Carr’s index (%) Hausner’s ratio
FSF1 27.64±0.04 0.867±0.08 1.057±0.06 15.06±0.04 1.20±0.03
FSF2 25.73±0.06 0.886±0.04 1.063±0.04 14.18±0.02 1.20±0.06
FSF3 23.44±0.07 0.897±0.03 1.058±0.07 13.13±0.06 1.18±0.04
FSF4 20.39±0.05 0.913±0.07 1.059±0.02 12.32±0.04 1.16±0.07
FSF5 26.52±0.05 0.514±0.06 0.611±0.09 15.17±0.06 1.188±0.05
FSF6 26.14±0.07 0.522±0.05 0.619±0.08 15.087±0.05 1.185±0.05
FSF7 25.73±0.03 0.524±0.09 0.620±0.07 15.48±0.04 1.183±0.08
FSF8 26.71±0.04 0.527±0.07 0.622±0.05 15.07±0.03 1.180±0.09
FSF9 27.64±0.03 0.514±0.02 0.611±0.085 14.87±0.07 1.188±0.06
FSF10 26.93±0.05 0.519±0.05 0.614±0.05 15.10±0.07 1.183±0.08
FSF11 26.10±0.07 0.521±0.06 0.616±0.07 15.42±0.03 1.182±0.07
FSF12 26.75±0.04 0.531±0.08 0.627±0.09 15.31±0.05 1.181±0.09
FSF13 28.26±0.06 0.783±0.04 0.955±0.05 15.72±0.07 1.22±0.05
FSF14 26.45±0.07 0.799±0.05 0.958±0.04 14.36±0.05 1.20±0.02
FSF15 24.87±0.04 0.914±0.02 1.078±0.07 13.74±0.06 1.18±0.04
FSF16 22.66±0.03 0.928±0.08 1.076±0.06 12.71±0.04 1.16±0.03
FSF17 24.02±0.21 0.439±0.012 0.512±0.022 14.24±0.02 1.16±0.012
FSF18 25.22±0.13 0.445±0.009 0.522±0.012 13.94±0.03 1.17±0.09
*All readings were taken in triplicate (n=3). SD+Mean
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stretching, and CH3 deformations, 1561.69 cm−1 indicating C=C, and 
1692.98 cm−1 corresponding to C=O, respectively. FTIR spectra of the 
physical mixture, i.e., optimized batch show almost nearest frequency 
range and near similar to the corresponding concurrent absorption of 
both the fluvastatin and added polymer molecules in same region of the 
FTIR spectra. Based on above evidence, the FTIR spectra of optimized 
batch depicted that there were no chances of any significant changes in 
the peak of fluvastatin sodium, as in making comparison of individual 
peaks as shown in pure fluvastatin (Fig. 1). The band at 3456 cm−1 is 
attributed to hydroxyl stretching in HPMC which was shifted to 3644.11 
in optimized batch and also a peak at 1692.98 cm−1 which indicates 
the presence of C=O stretching in optimized batch, this clearly gives 
an idea about occurrence of acidic esterification between sodium 
alginate and HPMC. It is clearly suggesting that there were no physical 
or chemical interactions and there was no change in functional group 
of optimized batch, as shown in Fig. 5. From the Fig. 5, it was observed 
that similar peaks were also reported in optimized formulation, few 
of them listed here include. There was no marked change or large 
shifting of characteristic peaks in drug-loaded microbeads and which 
suggested that there were no significant drug-polymer interactions, 
which indicates the stable nature of the fluvastatin drug in optimized 
formulation. Frequency range of spectra of various polymers, drug and 
optimized are shown in Figs. 1-5.
Morphology of microbeads
The formed microbeads are somewhat resembles with spherical in 
shape, discrete and surface covered with wrinkled layer which might be 
indication for occurrence of egg-box model structure that cross-linked 
by G-guluronic acid in sodium alginate molecules with polymer blend 
and AlCl3.
The SEM photograph of fluvastatin sodium showed that microspheres 
were spherical in shape and also few microbeads posses surface 
are with smooth indicating uniform distribution of the drug in the 
polymeric matrix of the polymer. The SEM analysis also revealed 
that the prepared microbeads were found to devoid of aggregation 
microbeads and posses any kind of negligible surface charges this 
clearly indicating physical stability of microbeads. Significant effect was 
observed in shape of microbeads on increasing the equal concentration 
of polymer blend. The SEM of optimized microsphere formulation of 
fluvastatin sodium is shown in Fig. 6.
DSC studies
DSC studies were used to examine the crystallization and melting 
behaviors of pure drug and optimized batch. A sharp melting point at 
120.89°C indicates its crystalline nature (Fig. 7). The temperature of 
the melting peak of fluvastatin in the microbeads, i.e., optimized batch 
Fig. 1: Fourier transform infrared spectrum of pure fluvastatin sodium
Fig. 2: Fourier transform infrared spectrum of pure sodium alginate
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Fig. 4: Fourier transform infrared spectrum of physical mixture containing sodium alginate with hydroxypropyl methylcellulose K4M
Fig. 5: Fourier transform infrared spectrum of optimized formulation
Fig. 3: Fourier transform infrared spectrum of pure hydroxypropyl methylcellulose K4M
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FLF8 exhibited same a sharp endothermic peak as in pure drug at 
114.35°C reflecting that near almost same temperature and other peaks 
at 178.11°C and 283.17°C indicates components were interacted each 
other while and evaporation of solvent on heating during the process. 
On examination of both DSC spectra of pure drug and optimization 
batch, the disappearance of endothermic peaks (178.11°C) in optimized 
batch revealed and proves that fluvastatin exists in optimized batch 
(FLF8) in an uncrystallized form rather than exists in crystalline form 
as in pure drug and drug molecules have been distributed throughout 
polymer matrix bead and it also explained as the DSC thermogram of 
optimized fluvastatin batch does not show marked profound shifts 
in peaks in comparison to pure DSC spectra of fluvastatin indicating 
compatibility and thermographic results not showing any sign of 
reaction and existence of stability after the preparation.
XRD properties
The X-ray powder diffraction technique acts as powerful analytical 
tool in the identification of crystalline and non-crystalline phase. 
The characteristic diffraction peaks of fluvastatin sodium are at the 
characteristics diffraction peaks of fluvastatin are at (2θ) 11.1311°, 
11.9581°, 12.8641°, 13.9792°, 15.552°, 16.455°, 17.3989°, 18.6393°, 
19.6992°, 20.6741°, 21.5800°, 22.3000°, 23.8534°, 24.6427°, 25.6400°, 
26.0836°, 26.6400°, 28.1321°, 30.3000°, 31.9000°, 32.3200°, 33.8940°, 
34.9600°, 35.5000°, 36.4200°, 37.0000°, 38.9920°, 41.0975°, 42.1366°, 
42.1366°, 42.8481°, and 44.4573° indicates the crystalline nature 
of the drug. Moreover, peaks of individual fluvastatin drug were still 
detectable in their respective optimized formulation with dramatically 
maximum reduction in intensity of peaks, and in optimized batch the 
much diffused pattern manner was observed in FSF8 batch which gives 
clear indication of conversion of crystalline state to the amorphous 
nature of drug. Thus, there is no indication of any interaction were 
identified in optimized formulation under the standard conditions. The 
X-ray powder diffraction studies of fluvastatin sodium and optimized 
batch are shown in Fig. 8.
Wash-off studies
The microbeads consisting of sodium alginate alone and in combination 
with HPMC K4M, exhibited good mucoadhesive properties as observed 
in in vitro wash-off test when compared to microbeads prepared with 
non-mucoadhesive polymer ethyl vinyl acetate (EVA). The wash off was 
slow in the case of microbeads consisting of alginate-mucoadhesive 
polymers (hydrophilic nature) when compared to that of ethyl cellulose 
microspheres (Table 3). The wash off was faster at simulated intestinal 
pH (phosphate buffer 6.8) than comparison to that at simulated gastric 
pH (1.2). Swelling of the study depends on that the solubility, hydration, 
and mucoadhesivity of the polymers depend on the pH of the medium 
used. The rapid wash-off observed at simulated intestinal pH may be 
due to the ionization of carboxyl acid group in sodium alginate polymer 
and other functional groups present in the polymers, which increase 
Fig. 8: X-ray diffraction spectra of pure fluvastatin drug (above spectra) and optimized batch (below spectra)
Fig. 6: Scanning electron microscope photograph of fluvastatin 
microbeads (left side) photographic image (right side)
Fig. 7: Differential scanning calorimetry thermogram of pure fluvastatin (above spectra) and optimized batch (below spectra)
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their solubility and reduce adhesive strength. The mucoadhesive 
behaviors of various microbeads formulations are shown in Fig. 9. The 
developed mucoadhesive microbeads would adhere strongly because 
of high viscosity of polymer blend, maximum swelling of microbeads in 
alkaline medium than acidic medium and thereby to enhance the surface 
area of microbeads to the gastrointestinal mucous walls and also cause 
high relaxation of polymers chains and resisting gastric emptying time. 
This would cause to ensure the prolong residence time at the mucous 
absorption site to promote further intimate contact with the absorption 
surface and thereby to enhance the rate of bioavailability of drug.
Determination of swelling index
It was determined by studying in two different dissolution media 
naming [10,11]. 0.1 N HCl for the first 2h and later the previous medium 
was replaced with 6.8 phosphate buffer medium under temperature 
at 37±0.5°C with 100 rpm and this test will be continued for 8 h with 
non-stop procedure using dissolution test apparatus USP model and 
basket (not paddle type) is used to hold microbeads inside which was 
ready to examine the swelling index. The measurement of swelling 
index of fluvastatin microbeads formulations using polymer blends of 
sodium alginate and HPMC K4M was carried out (FSF8 batch). This 
was conceptualized that high amount of polymer blend concentration, 
i.e., 3% w/v in equal proportions of sodium alginate and HPMC K4M 
absorbs huge quantity of solvent under alkaline conditions from 
the system in comparison to acidic medium and forms tight jelly like 
network around the surface of the microbeads with respect to the 
time t. This mechanical feature of surface hydrated polymer forms 
a viscous barricade that plays a major role in the whole amount of 
drug release rate. The swelling profiles for three different batches are 
shown in Fig. 9. However, interesting point in swelling rate after 8 h 
was observed in FSF8 batch than FSF17 and FSF18 that could be due to 
the reason of selection of different curing agents in above two different 
batches. In FSF8 batch been formulated using 5% w/v of AlCl3, as it 
forms three-dimensional network in cross-linking and forms very rigid 
surface microbeads which does not allow easily diffusion of solvent into 
the interior surface of the cross-linked beads, so in connection to this 
point the microbeads prepared with FSF8 formulation they will not 
undergoes maximum rate of swelling, i.e., less swelling (75.20%/8 h) 
than other batches that designed with BaCl2 (FSF17) and CaCl2 (FSF18) 
at the same concentrations with same polymer blend (Table 4). The 
maximum rate of swelling 97.47%/8 h was observed in FSF18 batch, 
which formulated with CaCl2 (divalency nature) and it allows easy 
diffusion of solvent into network of microbeads so that it leads to form 
maximum rate of swelling of all selected batches. The optimized batch 
containing HPMC K4M along with sodium alginate showed continuous 
increase in swelling. This may be again due to high proportion of 
polymeric system which retain water and form a thick swollen mass 
and minimize the erosion property of HPMC K4M (Fig. 10).
Model dependent kinetics
The drug release kinetics for all 18 batches was calculated using Microsoft 
Office Excel 2007 version. The release data were analyzed by fitting the 
profile of drug release of all the formulations into different kinetic orders 
which naming zero-order [12], first-order, Higuchi, and Korsmeyer–
Peppas model, and regression coefficients (R2) were calculated for all the 
formulations. The apparent dissolution rate constants Ko(mg/h), T50(h.) 
and T90(h). However, all batches posses maximum R2 value (Regression 
coefficient) ranging from 0.9771 to 0.998 indicates zero-order drug 
release and maximum diffusion exponent value “n” 1.182 for optimized 
batch suggesting super Case-II transport mechanism.
The mechanism of fluvastatin based sodium alginate discharge from the 
hydrophilic matrix carrier system involves polymer swelling/erosion 
and non-Fickian diffusion of the drug. The parameters are shown in 
Table 5.
Fig. 9: Adherence of fluvastatin-based sodium alginate 
microbeads around mucous tissue specimen during wash-off test
Table 4: Swelling index values of fluvastatin sodium alginate 
microbeads prepared with a combination of sodium alginate 
and HPMC K4M in 1.5:1.5 ratio by employing various 
cross-linking agents
Formulation code Swelling index
Time (h)
After 1 h After 2 h After 8h
FSF8 23.45 33.82 75.20
FSF17 26.72 49.44 89.68
FSF18 30.67 57.13 97.47
*Each reading taken in triplicate manner, i.e., n=3. HPMC: Hydroxypropyl 
methylcellulose
Fig. 10: Comparative swelling index plot of fluvastatin sodium alginate microbeads prepared with a combination of sodium alginate and 
hydroxypropyl methylcellulose K4M in 1:3 ratios by employing various types of cross-linking agents. FSF8 ( ) Fluvastatin sodium 
alginate microbeads prepared with a combination of sodium alginate and HPMC K4M in 1:3 ratio by employing aluminum chloride. 
FSF17(-■-) Fluvastatin sodium alginate microbeads prepared with a combination of sodium alginate and HPMC K4M in 1:3 ratio by 
employing barium chloride. FSF18(-▲-) Fluvastatin sodium alginate microbeads prepared with a combination of sodium alginate and 
HPMC K4M in 1:3 ratio by employing calcium chloride. *Each reading taken in triplicate manner, i.e., n=3.
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Dissolution studies
The pattern could be controlled by the alginate gel disintegration 
in both 0.1 N HCl acid for the first 2 h and continued the study up to 
12 h by replacing previous medium freshly prepared 6.8 phosphate 
buffer solution at 37±0.5°C under 100 rpm using paddle-type in vitro 
dissolution test apparatus. The breakdown or slow fragmentation of 
soft swellable alginate microbeads was monitored by the exchange 
of Al3+ from FSF1 to FSF8 batches with potassium ions present in the 
6.8 potassium phosphate buffer dissolution medium. The drug release 
mainly relies on diffusion of drug through the small pores and cracks 
which are formed on surface of wet swellable microbeads during 
dissolution process under standard conditions.
The release behavior of alginate microbeads, produced by internal 
gelation with different gelling agents relies on the size and valence of the 
cations of the respective cross-linking agents at 5% w/v. To investigate 
this mechanism, the polymer blend consists of sodium alginate 1.5% 
w/v sodium alginate and 1.5% w/v of HPMC K4M were added with 
various cross-linking agents at 5% w/v concentrations naming AlCl3+ 
(FSF8 batch), BaCl2+ (FSF17), and CaCl2+ (FSF18) and their impact on 
drug release was studied.
The slow release of fluvastatin through the insoluble cross-linked 
matrix of blend polymer occurs in 0.1 N HCl dissolution medium and 
very slow rate of swelling takes place in prepared microbeads and it 
results in only small quantity of drug release in acidic medium, in 
contrast to this, swelling and erosion of the microbeads prepared 
from polymer blend were highly observed in phosphate buffer of pH 
6.8. Slow erosion of aluminum cross-linked fluvastatin based alginate 
microbeads could occur through slight degradation of sodium alginate 
backbone into smaller species.
The FLF8 batch in equal proportions of 1.5:1.5 containing polymer 
blend of sodium alginate and HPMC K4M retard or produces sustain 
the release of drug from the microbeads compared to other batches. 
The slow amount of drug release is due to swelling of HMPC K4M that 
makes in delays of drug release from the cross-linked microbeads. The 
drug release patterns of all eighteen batches are shown in Figs. 11-13. 
Due to the result of the rheology [13] of hydrated/swelled product, 
the swollen particles combine. This outcome in a non-stop viscoelastic 
matrix that fills the interstices, keeping the integrity of the microbeads, 
and hindering further entry of the dissolution medium into microbeads 
containing a higher amount (1.5% w/v) of HPMC K4M.
Table 5: In-vitro dissolution kinetics parameters of fluvastatin microbeads prepared with sodium alginate alone and in combination 
with hydroxypropyl methylcellulose K4M/Carbopol 934 P/NaCMC in different ratios by employing aluminum chloride/barium 
chloride/calcium chloride as a cross-linking agent at 5% w/v
Formulation Correlation coefficient (R2) Release kinetics Diffusionexponent value(n)
Zero order First order Higuchi Peppas Ko (mg/h) T50 (h) T90 (h)
FSF1 0.9992 0.7245 0.8952 0.9902 5.17 3.86 6.96 0.8956
FSF2 0.9985 0.7326 0.9117 0.9948 4.82 4.14 7.46 0.8848
FSF3 0.9976 0.7683 0.9178 0.9946 4.41 4.53 8.16 0.8778
FSF4 0.9979 0.7709 0.9315 0.9968 3.56 5.61 10.11 0.8500
FSF5 0.9996 0.8056 0.9303 0.9990 4.72 4.23 7.62 0.9112
FSF6 0.9989 0.7971 0.9107 0.9998 4.4 4.5 8.18 1.082
FSF7 0.9986 0.8073 0.9214 0.9985 3.84 5.1 9.2 1.108
FSF8 0.9983 0.6380 0.9052 0.9991 3.28 6.09 10.97 1.182
FSF9 0.9976 0.7964 0.9404 0.9975 4.96 4.03 7.25 0.8418
FSF10 0.9998 0.8044 0.9268 0.9995 4.64 4.31 7.75 0.9427
FSF11 0.9994 0.8068 0.9228 0.9928 4.08 4.9 8.82 1.0301
FSF12 0.9998 0.7640 0.9261 0.9993 3.60 5.5 10.0 1.1035
FSF13 0.9778 0.7407 0.9089 0.9941 5.70 3.50 6.31 0.8883
FSF14 0.9771 0.7705 0.9167 0.9960 4.80 4.16 7.5 0.8802
FSF15 0.9910 0.7991 0.9278 0.9971 4.50 4.44 8.0 0.8748
FSF16 0.9978 0.8085 0.9352 0.9983 3.94 5.07 9.13 0.8649
FSF17 0.9990 0.7235 0.9126 0.9966 3.48 5.74 10.32 0.8801
FSF18 0.9976 0.7478 0.9168 0.9934 3.60 5.55 10.0 0.9023
Fig. 11: Dissolution profile of batches from FSF1 to FSF6. Each value taken in triplicate, i.e., n=3. Mean±SD
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Fig. 13: Dissolution profile of batches from FSF13 to FSF18. Each value taken in triplicate, i.e., n=3. Mean±SD
Fig. 14: Comparative dissolution profile of optimized batch FSF8, marketed product, and pure drug. Each value taken in triplicate, i.e., n=3. 
Mean±SD
Fig. 12: Dissolution profile of batches from FSF7 to FSF12. Each value taken in triplicate, i.e., n=3. Mean±SD
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The outcomes acquired can be clarified on the basis of the extent of cross-
linking in the microspheres. In case of CaCl2 and BaCl2 used as hardening 
agents in batches (FSF18 and FSF17) and of their divalence nature, 
they form two-dimensional network bonding structure with sodium 
alginate chain inside the cross-linked alginate matrices. In case of Ba2+ 
it has the largest size (1.74 A°) when compared to the other two curing 
agents (0.68 A° for Al3+and 1.14 A° for Ca2+) it is expected to form strong 
alginate microspheres with little voids and minimum water uptake. 
Along these lines, the exchange of larger barium ions in the microbeads 
with potassium ions of dissolution medium (phosphate buffer, pH 6.8) 
and furthermore, their expulsion as insoluble barium phosphate was 
upset, and this resulting in delayed swelling rate of the microbeads and 
slow release of drug occurs. In case of calcium alginate microbeads, due 
to the smaller size of Ca2+ ions as compared to barium ions, it ensures 
fast removal of calcium as calcium phosphate from the microbeads 
due to process of ion exchange with potassium of 6.8 phosphate buffer 
medium and thus leading to greater amount of fluid uptake and this leads 
to cause maximum release of drug. In case of Al3+alginate microbeads, 
this deferral was taken place and it was due to the ability of Al3+ to form 
three-dimensional bonding network bonding structure with the sodium 
Table 6: Drug content, encapsulation efficiency, and dissolution kinetics of fluvastatin sodium alginate microbeads stored at 
25±2°C/60±5% RH and 40±2°C/75±5% RH
Storage conditions Time interval Drugcontent Encapsulationefficiency Release rate constant(mg/h) Ko t50% t90%
25±2°C/60±5% RH 1st month 24.40 97.60 3.28 6.09 10.97
2nd month 24.38 97.52 3.28 6.09 10.97
3rd month 24.35 97.40 3.28 6.09 10.97
40±2°C/75±5% RH 1st month 24.37 97.48 3.28 6.09 10.97
2nd month 24.34 97.36 3.28 6.09 10.97
3rd month 24.32 97.28 3.28 6.09 10.97
*Each value taken in triplicate. n=3
Table 7: In-vitro dissolution data of fluvastatin cross-linked sodium microbeads stored at 25±2°C/60±5% RH and 40±2°C/75±5% RH 
after 3 months stability studies
S.No. Time (h) Initial Percentage of fluvastatin sodium released (X±SD)
25±2°C/60±5% RH 40±2°C/75±5% RH
1st month 2nd month 3rd month 1st month 2nd month 3rd month
1. 0 0 0 0 0 0 0 0
2. 0.5 2.94±0.15 2.84±0.09 2.76±0.13 2.67±0.06 2.72±0.13 2.64±0.08 2.55±0.05
3. 1 7.02±0.08 6.93±0.14 6.86±0.06 6.75±0.13 6.81±0.11 6.73±0.09 6.66±0.08
4. 1.5 11.68±0.15 11.57±0.10 11.48±0.08 11.40±0.09 11.45±0.14 11.39±0.11 11.13±0.05
5. 2 15.81±0.11 15.72±0.11 15.64±0.05 15.64±0.05 15.57±0.06 15.43±0.10 15.36±0.11
6. 2.5 17.25±0.06 17.16±0.15 17.07±0.09 16.98±0.09 17.06±0.05 16.97±0.11 16.85±0.10
7. 3 21.42±0.11 21.33±0.13 21.26±0.11 21.14±0.15 21.19±0.13 21.12±0.06 21.04±0.13
8. 3.5 25.61±0.09 25.52±0.09 25.43±0.13 25.33±0.09 25.39±0.09 25.32±0.08 25.25±0.11
9. 4 29.82±0.11 29.73±0.06 29.64±0.15 29.54±0.06 29.59±0.15 29.53±0.13 29.46±0.09
10. 4.5 34.05±0.08 33.96±0.08 33.87±0.06 33.77±0.08 33.82±0.13 33.74±0.09 33.65±0.08
11. 5 38.31±0.06 38.22±0.10 38.13±0.09 38.02±0.13 38.09±0.10 38.02±0.15 37.94±0.06
12. 5.5 42.58±0.11 42.49±0.08 42.40±0.05 42.30±0.06 42.37±0.05 42.31±0.10 42.27±0.09
13. 6 46.88±0.06 46.80±0.11 40.71±0.06 46.60±0.11 46.66±0.11 46.59±0.06 46.43±0.11
14. 6.5 51.21±0.15 51.12±0.14 51.03±0.05 50.92±0.10 50.98±0.13 50.91±0.08 50.83±0.10
15. 7 55.55±0.09 55.47±0.09 55.39±0.11 55.26±0.15 55.32±0.05 55.26±0.06 54.97±0.13
16. 7.5 59.92±0.15 59.84±0.13 59.76±0.08 59.63±0.09 59.69±0.15 59.61±0.13 59.54±0.15
17. 8 64.31±0.08 64.22±0.11 64.13±0.10 64.02±0.06 64.09±0.09 64.03±0.11 63.94±0.10
18. 8.5 68.73±0.11 68.64±0.14 68.54±0.13 68.45±0.11 68.51±0.06 68.44±0.08 68.37±0.11
19. 9 73.16±0.06 73.08±0.12 72.99±0.09 72.90±0.09 72.99±0.08 72.92±0.09 72.57±0.13
20. 9.5 77.62±0.15 77.54±0.15 77.43±0.06 77.32±0.06 77.37±0.09 77.31±0.11 77.43±0.15
21. 10 82.1±0.09 82.07±0.13 81.91±0.08 81.80±0.08 81.86±0.05 81.80±0.09 81.73±0.09
22. 10.5 86.61±0.11 86.52±0.10 86.44±0.15 86.31±0.13 86.38±0.06 86.32±0.10 86.26±0.10
23. 11 91.13±0.08 91.07±0.11 90.95±0.10 90.83±0.10 90.89±0.10 90.83±0.13 90.76±0.13
24. 11.5 95.41±0.09 95.33±0.13 95.25±0.09 95.16±0.14 95.21±0.15 95.16±0.09 95.08±0.15
25. 12 99.98±0.12 99.90±0.10 99.82±0.11 99.72±0.13 99.79±0.09 99.73±0.06 99.66±0.08
*Each value taken in triplicaten=3. Mean±SD
alginate inside the microbeads. This three dimensional bonding results 
in an extended cross-linking through the whole microbeads, producing 
rigid and compact surface of cross-linked alginate microbeads with low 
amount of water uptake and it leading to slow removal of Al3+ due to 
ion exchange with potassium ions present in the 6.8 phosphate buffer 
medium. As a result, the swelling of the soft cross-linked beads is delayed 
and it leading to slow disintegration of microbeads.
The percent of drug release for FSF8 batch to reach T90 is 10.97 h, 
towards FSF17 batch 10.32 h and for FSF18 batch it was took 10 h. 
Hence, on the basis of above long discussion regarding drug release 
data, only FSF8 batch will provide SR up to 12 h and it leads to reduce 
the frequency of drug administration, so to minimize the incidence of 
side effects, thereby to improve patience compliance.
There is change observed on surface of the microbeads after dissolution 
experiment showed presence of microns size of pores which gives 
the indication that the fluvastatin drug was released occurs through 
these pores slowly by swelling and the mechanism of drug release 
was completely swelling and diffusion-controlled based. The diffusion 
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exponent “n” for optimized batch is 1.182 that indicates drug release 
follows super Case II transport mechanism controlled by both swelling 
and relaxation of the polymer chains. The drug release of optimized 
batch FSF8 were compared to pure drug and marketed tablet of same 
strength of drug to elucidate the difference and progress in achievement 
of controlled drug release of optimized batch. The drug release profile 
of pure drug, optimized batch, and marketed product (Lescol ER) is 
shown in Fig. 14. All readings were taken in triplicate, i.e., n=3.
Stability studies
The optimized formulation FSF8 was subjected to stability studies at 
both room temperature i.e., 28°C and 45°C/75% RH and evaluated 
for their drug content, DEE, release rate constant and in vitro drug 
release. Only small negligible changes were observed in the different 
physicochemical parameters at different temperatures, i.e., 28°C and 
45°C/75% RH which studied for 3 months under standard conditions 
and as per International Council for Harmonisation (ICH) guidelines 
(Tables 6 and 7). The details of in vitro data after stability studies done 
for 3 months at different temperature and humidity conditions are 
shown in Table 7, and details of drug content, entrapment efficiency, 
release rate constant, t50% and t90% with respect to monthly wise up to 
3 months are shown in Table 6.
CONCLUSION
Among all the formulations, fluvastatin loaded mucoadhesive microbeads 
prepared with sodium alginate and HPMC K4M (FSF8 batch) in equal 
proportion of 1.5:1.5 shows CR up to 12 h. Effect of various factors such 
as concentration of polymer, combination of sodium alginate with other 
polymers, type of cross-linking agent effect, and concentration of polymer 
blend was studied. Using emulsification-internal gelation technique, 
it is possible to obtain a maximum drug entrapment efficiency of 
97.84±0.07%. It was clear that as the quantity of the polymer is increases, 
the rate of drug release is reduced and microbeads prepared with AlCl3 
as a curing agent only provides CR of drug. The formed microbeads were 
spherical in shape and fluvastatin remained distributed in the polymer 
matrix at amorphous state which was proved by X-ray diffraction studies, 
it proves clearly that the rate of bioavailability of drug was enhanced. 
The prepared microspheres exhibited good mucoadhesive properties as 
observed in in vitro wash-off test when compared to a non-mucoadhesive 
polymer, EVA microbeads. The drug release mechanism was Case II 
transport kinetic model type which indicates drug release occurs by both 
swelling and relaxation of microbeads. There was no significant change 
in drug entrapment and drug release profile when stored at different 
storage atmospheric conditions as it is proved by conducting stability 
studies as per the ICH guidelines.
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